After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Biomarin Pharmaceutical Inc is $13.55B. A total of 1.71 million shares were traded on the day, compared to an average of 1.55M shares.
Insider Activity
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, BMRN has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
In the most recent transaction, Burkhart Erin sold 1,344 shares of BMRN for 68.38 per share on Feb 24 ’25. After the transaction, the GVP, Chief Accounting Officer now owns 13,105 company shares. In a previous transaction on Feb 24 ’25, Burkhart Erin bought 1,344 shares at 68.38 per share.
Among the insiders who sold shares, Guyer Charles Greg disposed of 5,278 shares on Nov 12 ’24 at a per-share price of $66.37. This resulted in the EVP, Chief Technical Officer holding 68,909 shares of BMRN after the transaction. In another insider transaction, Guyer Charles Greg bought 5,278 shares at $66.37 per share on Nov 12 ’24.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for BMRN in the last 3 months, the mean price target is $97.32 with high estimates of $126.00 and low estimates of $65.00. In terms of 52-week highs and lows, BMRN has a high of $94.85 and a low of $60.63.
As of this writing, BMRN has an earnings estimate of $0.97 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of $1.16 per share and a lower estimate of $0.71.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BMRN’s latest balance sheet shows that the firm has $1.01B in Cash & Short Term Investments as of fiscal 2021. There were $1.09B in debt and $546.50M in liabilities at the time. Its Book Value Per Share was $29.66, while its Total Shareholder’s Equity was $4.27B.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMRN is Buy with a score of 4.56.
